|
Post by kbrion77 on Apr 21, 2017 15:16:04 GMT -5
Congratulations! But it's not FUD. There is only one FACT here. Afrezza's scripts aren't increasing. While we all hope that will change. The reality is what it is... The new sales force hasn't had a meaningful impact on scripts. Why? We can't blame it all on lack of insurance coverage. We can't blame it all on price, MannKind is offering discounts, etc. Afrezza is easy to take... just inhale. So, what's the problem? There has to be a problem, because there is obviously been something that hasn't been addressed or can't be addressed. What's left? Dosing. And, Doctor reluctance to have patients try Afrezza. Afrezza is a product that requires patients to actively monitor their disease and dose with Afrezza appropriately to stay within optimal levels. This is obviously creating user adoption issues, and docs aren't willing to give patients that kind of responsibility. Doc's want to be able to say "take one pill, or two pills" or "one shot" etc. So in the real world patients aren't taking enough Afrezza, or compensating (upwards) when it doesn't work as expected. Docs can only hold patients hands so much. ----- Let's put it this way. I'm an IT guy. It's easy... everything you need to know to fix almost any problem is out there on the Internet. Still users don't want to figure it out, even if the answer is 30sec. away on Google. I get a lot of calls... So back to Afrezza, Docs are reluctant to prescribe Afrezza because they will be getting calls all day long. It doesn't matter if it's easy it's still wasting the docs time. If Afrezza had the "superior" label maybe it would be worth it. But it doesn't, and marginally improved outcomes isn't enough to justify the hassle. Am I reaching? Yes. Am I putting words in docs mouths? Yes Am I making conclusions based on to little information? Yes Has anyone come up with a better explanation? No My conclusion is Afrezza is a niche product, and that's really bad for MannKinds future. Take a look at my posting history. I was as optimistic as anyone and have never been Short MNKD. What benefit would I have for spreading FUD. None. If I needed to use Afrezza I expect I'd have a "superior" outcome. I'm a "figure it out" kind of guy... I wouldn't really need my doc. But docs aren't prescribing for me. They're going to assume they're prescribing for the lowest common denominator. So, unless the patient demands Afrezza, they're going to look elsewhere. I hope I'm wrong, but everything I've seen says I'm right. A niche product in the diabetes sector could be $100MM-$200MM in annual revenues. Afrezza is on pace for $10MM. This product as of right now is a failure not a niche. Your post was too nice lol.
|
|
|
Post by mnkdfann on Apr 21, 2017 15:43:12 GMT -5
Bounced off 0.89 like the Olympic gold medallist gymnast Rosie MacLennan off a trampoline! youtu.be/xh4ohmllf3o
|
|
|
Post by peppy on Apr 24, 2017 12:39:10 GMT -5
|
|
|
Post by kbrion77 on Apr 24, 2017 12:46:54 GMT -5
Rinse and repeat........
|
|
|
Post by peppy on Apr 24, 2017 15:52:26 GMT -5
total volume today, real time, 2,251,188 90 cents. www.nasdaq.com/symbol/mnkd/real-timenumber of shares 92,085,000 per consolidated statements of operations. todays trading volume = 2.4 % of shares.
|
|
|
Post by peppy on Apr 25, 2017 9:05:44 GMT -5
real time nasdaq MNKD trading volume at 30 minutes of trade, 518,403 shares. .94 .96 resistance. it sure would be nice if price got above 1 dollar again.
|
|
|
Post by gamblerjag on Apr 25, 2017 9:18:01 GMT -5
real time nasdaq MNKD trading volume at 30 minutes of trade, 518,403 shares. .94 .96 resistance. it sure would be nice if price got above 1 dollar again. . It will peppy it will. All we need is one day over a dollar and it resets the clock for the next 30 good luck
|
|
|
Post by peppy on Apr 25, 2017 9:32:57 GMT -5
great
|
|
|
Post by sportsrancho on Apr 25, 2017 9:50:22 GMT -5
great Peppy my calls just doubled. ^soon:-)
|
|
|
Post by fanz8967 on Apr 25, 2017 9:56:12 GMT -5
great Peppy my calls just doubled. ^soon:-) I'm doing what SportsRancho is doing, she is young and positive and smart and beautiful. If she's holding, I'm holding. Me, her and Peppy can start the girls club. All of the the rest of you can keep bashing to each other. I'm ignoring all of the negative Nancys.
|
|
|
Post by peppy on Apr 26, 2017 12:17:50 GMT -5
|
|
|
Post by dreamboatcruise on Apr 26, 2017 12:28:34 GMT -5
I just bought a handful of $1.50 2019 calls. From my gambling money, not investment money.
|
|
|
Post by sportsrancho on Apr 26, 2017 13:22:39 GMT -5
I just bought a handful of $1.50 2019 calls. From my gambling money, not investment money. I'm going to buy as many 1 dollar 2019's as I can as soon as I have extra funds.
|
|
|
Post by peppy on Apr 28, 2017 7:06:11 GMT -5
|
|
|
Post by dejude42 on Apr 28, 2017 7:27:51 GMT -5
Congratulations! But it's not FUD. There is only one FACT here. Afrezza's scripts aren't increasing. While we all hope that will change. The reality is what it is... The new sales force hasn't had a meaningful impact on scripts. Why? We can't blame it all on lack of insurance coverage. We can't blame it all on price, MannKind is offering discounts, etc. Afrezza is easy to take... just inhale. So, what's the problem? There has to be a problem, because there is obviously been something that hasn't been addressed or can't be addressed. What's left? Dosing. And, Doctor reluctance to have patients try Afrezza. Afrezza is a product that requires patients to actively monitor their disease and dose with Afrezza appropriately to stay within optimal levels. This is obviously creating user adoption issues, and docs aren't willing to give patients that kind of responsibility. Doc's want to be able to say "take one pill, or two pills" or "one shot" etc. So in the real world patients aren't taking enough Afrezza, or compensating (upwards) when it doesn't work as expected. Docs can only hold patients hands so much. ----- Let's put it this way. I'm an IT guy. It's easy... everything you need to know to fix almost any problem is out there on the Internet. Still users don't want to figure it out, even if the answer is 30sec. away on Google. I get a lot of calls... So back to Afrezza, Docs are reluctant to prescribe Afrezza because they will be getting calls all day long. It doesn't matter if it's easy it's still wasting the docs time. If Afrezza had the "superior" label maybe it would be worth it. But it doesn't, and marginally improved outcomes isn't enough to justify the hassle. Am I reaching? Yes. Am I putting words in docs mouths? Yes Am I making conclusions based on to little information? Yes Has anyone come up with a better explanation? No My conclusion is Afrezza is a niche product, and that's really bad for MannKinds future. Take a look at my posting history. I was as optimistic as anyone and have never been Short MNKD. What benefit would I have for spreading FUD. None. If I needed to use Afrezza I expect I'd have a "superior" outcome. I'm a "figure it out" kind of guy... I wouldn't really need my doc. But docs aren't prescribing for me. They're going to assume they're prescribing for the lowest common denominator. So, unless the patient demands Afrezza, they're going to look elsewhere. I hope I'm wrong, but everything I've seen says I'm right. A niche product in the diabetes sector could be $100MM-$200MM in annual revenues. Afrezza is on pace for $10MM. This product as of right now is a failure not a niche. Your post was too nice lol. Personally I like the word niche Cambridge Dictionary defines: a job, position, or place that is very suitable for someone. Afrezza holds each of the define spots. The job fastest lowering, the position FDA Approved and the place to use anywhere without obstruction. These are just a few of the held definition possibilities.
|
|